Perspective Chapter: Testing for Lupus Anticoagulant – Is There Light at the End of the Tunnel?

Read full text Summarise with VIRAT
Authors: Kamal Fatmawati
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. The diagnosis of SLE is challenging due to its heterogeneous nature and complex clinical manifestations. Lupus anticoagulant (LA) is a nonspecific plasma inhibitor, also known as an antiphospholipid antibody (APLA). It prolongs the prothrombin time (PT) and the activated partial thromboplastin time (APTT). It is associated with thrombosis rather than a bleeding tendency. It is one of the laboratory criteria for the diagnosis of SLE and antiphospholipid syndrome (APS). Despite its name, LA is not specific to SLE. The European League against Rheumatism (EULAR) and the American College of Rheumatology (ACR) assigned a positive anti-nuclear antibody (ANA) test as an entry criterion. Other features included in the immunological criteria are SLE-specific antibodies, complement proteins, and antiphospholipid antibodies, including lupus anticoagulants (LA), anticardiolipin antibodies (aCL), and anti-beta2-glycoprotein I (antiβ2GP1) antibodies. Detecting LA is challenging due to the lack of harmonisation in methods and algorithms. Recent guidelines were published to address several issues associated with LA testing.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Blood Coagulation and Thrombosis Mechanisms Vasculitis and related conditions

Publication details

Journal / source
IntechOpen eBooks
Publication date
12 March 2026
Language
EN
Document type
Book chapter